U.S. markets closed

Vericel Corporation (VCEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
61.35+0.37 (+0.61%)
At close: 4:00PM EDT
56.50 -4.85 (-7.91%)
After hours: 04:52PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close60.98
Open60.22
Bid43.00 x 1800
Ask65.00 x 800
Day's Range60.22 - 62.97
52 Week Range12.82 - 64.90
Volume836,749
Avg. Volume726,504
Market Cap2.844B
Beta (5Y Monthly)2.11
PE Ratio (TTM)689.33
EPS (TTM)0.09
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est66.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-30% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Vericel to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021
    GlobeNewswire

    Vericel to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021

    CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Goldman Sachs 42nd Annual Global Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, June 10, 2021, at 4:40 p.m. Eastern Time. A live webcast of the

  • Vericel Announces Appointment of Lisa Wright to Board of Directors
    GlobeNewswire

    Vericel Announces Appointment of Lisa Wright to Board of Directors

    CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Lisa Wright to its Board of Directors, effective immediately. Ms. Wright will serve as a member of the Governance and Nominating Committee of the Board. With the appointment of Ms. Wright, Vericel’s Board is now comprised of eight directors, seven of whom are independent. Ms. Wright is Presid

  • Vericel to Present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021
    GlobeNewswire

    Vericel to Present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021

    CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Canaccord Genuity Virtual Musculoskeletal Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, May 20, 2021, at 9:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel CorporationVericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com. Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved. Investor Contacts:Eric Burnsir@vcel.com+1 734-418-4411